

Express Mail No.: EY 531695774 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Zeldis

Confirmation No.: To Be Assigned

Application No.: 10/534,325

Group Art Unit: To Be Assigned

Filed: May 5, 2005

Examiner: To Be Assigned

For: METHODS AND COMPOSITIONS
USING SELECTIVE CYTOKINE
INHIBITORY DRUGS FOR THE
TREATMENT AND
MANAGEMENT OF CANCERS
AND OTHER DISEASES

Attorney Docket No.: 9516-207-999

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references **A01** to **A124**, **B01** to **B12**, and **C01** to **C61** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references **A01** to **A09**, **B01** to **B12**, and **C01** to **C61** are provided herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing reference and that the reference be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), Applicants estimate that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: September 9, 2005

by Yeatsil Moon
Anthony M. Insogna *Reg. No. 52,042* 35,203
Anthony M. Insogna (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosures

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

9516-207-999

APPLICATION NO.

10/534,325

APPLICANT

Zeldis

FILING DATE

May 5, 2005

GROUP

To Be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	60/499,723		Markian			9/4/03
	A02	60/454,149		Man et al.			3/12/03
	A03	60/452,460		Muller et al.			3/5/03
	A04	60/438,450		Muller et al.			1/7/03
	A05	60/438,448		Muller et al.			1/7/03
	A06	60/372,348		Hariri et al.			4/12/02
	A07	10/748,085		Zhang et al.			12/29/03
	A08	09/545,654		D'Amato			4/10/00
	A09	09/287,377		D'Amato			4/7/99
	A10	2005/0014727	1/20/05	Muller et al.			
	A11	2004/0266809	12/30/04	Emanuel et al.			
	A12	2004/0259873	12/23/04	Man et al.			
	A13	2004/0254214	12/16/04	Man et al.			
	A14	2004/0167199	8/26/04	Muller et al.			
	A15	2004/0127545	7/1/04	Green et al.			
	A16	2004/0122052	6/24/04	Muller et al.			
	A17	2004/0091455	5/13/04	Zeldis			
	A18	2004/0087546	5/6/04	Zeldis			
	A19	2004/0077686	4/22/04	Dannenberg et al.			
	A20	2004/0077685	4/22/04	Figg et al.			
	A21	2004/0029832	2/12/04	Zeldis			
	A22	2003/0235909	12/25/03	Hariri et al.			
	A23	2003/0191098	10/9/03	D'Amato			
	A24	2003/0187052	10/2/03	Schafer et al.			
	A25	2003/0187024	10/2/03	D'Amato			
	A26	2003/0185826	10/2/03	Tobinick			
	A27	2003/0181428	9/25/03	Green et al.			
	A28	2003/0144325	7/31/03	Muller et al.			
	A29	2003/0139451	7/24/03	Shah et al.			
	A30	2003/0113318	6/19/03	Tobinick			
	A31	2003/0069428	4/10/03	Muller et al.			
	A32	2003/0049256	3/13/03	Tobinick			
	A33	2003/0028028	2/6/03	Man et al.			
	A34	2003/0013739	1/16/03	Masferrer et al.			
	A35	2003/0007972	1/9/03	Tobinick			
	A36	2002/0183360	12/5/02	Muller et al.			

A37	2002/0173658	11/21/02	Muller et al.			
A38	2002/0161023	10/31/02	D'Amato			
A39	2002/0131955	9/19/02	Tobinick			
A40	2002/0131954	9/19/02	Tobinick			
A41	2002/0128228	9/12/02	Hwu			
A42	2002/0061923	5/23/02	D'Amato			
A43	2002/0054899	5/9/02	Zeldis			
A44	2002/0052398	5/2/02	D'Amato			
A45	2002/0045643	4/18/02	Muller et al.			
A46	2002/0035090	3/21/02	Zeldis et al.			
A47	2001/0056114	12/27/01	D'Amato			
A48	2001/0026801	10/4/01	Tobinick			
A49	2001/0018445	8/30/01	Huang et al.			
A50	2001/0016195	8/23/01	Tobinick			
A51	2001/0004456	6/21/01	Tobinick			
A52	6,699,899	3/2/04	Man et al.			
A53	6,667,316	12/23/03	Man et al.			
A54	6,623,736	9/23/03	Tobinick			
A55	6,537,549	3/25/03	Tobinick			
A56	6,518,298	2/11/03	Green et al.			
A57	6,518,281	2/11/03	Muller et al.			
A58	6,479,554	11/12/02	Muller et al.			
A59	6,471,961	10/29/02	Tobinick			
A60	6,469,045	10/22/02	D'Amato			
A61	6,458,810	10/1/02	Muller et al.			
A62	6,429,221	8/6/02	Muller et al.			
A63	6,428,787	8/6/02	Tobinick			
A64	6,423,321	7/23/02	Tobinick			
A65	6,420,414	7/16/02	D'Amato			
A66	6,419,944	7/16/02	Tobinick			
A67	6,419,934	7/16/02	Tobinick			
A68	6,403,613	6/11/02	Man et al.			
A69	6,395,754	5/28/02	Muller et al.			
A70	6,380,239	4/30/02	Muller et al.			
A71	6,379,666	4/30/02	Tobinick			
A72	6,326,388	12/4/01	Man et al.			
A73	6,284,780	9/4/01	Muller et al.			
A74	6,262,101	7/17/01	Muller et al.			
A75	6,235,756	5/22/01	D'Amato			
A76	6,214,857	4/10/01	Muller et al.			
A77	6,200,987	3/13/01	Muller			
A78	6,180,644	1/30/01	Muller et al.			
A79	6,177,077	1/23/01	Tobinick			
A80	6,140,346	10/31/00	Andrulis, Jr. et al.			
A81	6,130,226	10/10/00	Muller et al.			

	A82	6,114,355	9/5/00	D'Amato			
	A83	6,075,041	6/13/00	Muller			
	A84	6,046,221	4/4/00	Muller et al.			
	A85	6,020,358	2/1/00	Muller et al.			
	A86	6,015,557	1/18/00	Tobinick et al.			
	A87	6,011,050	1/4/00	Muller et al.			
	A88	5,968,945	10/19/99	Muller et al.			
	A89	5,955,476	9/21/99	Muller et al.			
	A90	5,929,117	7/27/99	Muller et al.			
	A91	5,877,200	3/2/99	Muller			
	A92	5,801,195	9/1/98	Muller et al.			
	A93	5,736,570	4/7/98	Muller et al..			
	A94	5,733,566	3/31/98	Lewis			
	A95	5,731,325	3/24/98	Andrulis, Jr. et al.			
	A96	5,728,845	3/17/98	Muller et al.			
	A97	5,728,844	3/17/98	Muller et al.			
	A98	5,712,291	1/27/98	D'Amato			
	A99	5,703,098	12/30/97	Muller et al.			
	A100	5,674,533	10/7/97	Santus et al.			
	A101	5,698,579	12/16/97	Muller			
	A102	5,658,940	8/19/97	Muller et al.			
	A103	5,639,476	6/17/97	Oshlack et al.			
	A104	5,605,914	2/25/97	Muller			
	A105	5,591,767	1/7/97	Mohr et al.			
	A106	5,580,755	12/3/96	Souza			
	A107	5,528,823	6/25/96	Rudy, Jr. et al.			
	A108	5,463,063	10/31/95	Muller			
	A109	5,393,870	2/28/95	Deeley et al.			
	A110	5,391,485	2/21/95	Deeley et al.			
	A111	5,385,901	1/31/95	Kaplan et al.			
	A112	5,354,556	10/11/94	Sparks et al.			
	A113	5,229,496	7/20/93	Deeley et al.			
	A114	5,134,127	7/28/92	Stella et al.			
	A115	5,120,548	6/9/92	McClelland et al.			
	A116	5,073,543	12/17/91	Marshall et al.			
	A117	5,059,595	10/22/91	Le Grazie			
	A118	4,999,291	3/12/91	Souza			
	A119	4,810,643	3/7/89	Souza			
	A120	4,008,719	2/22/77	Theeuwes et al.			
	A121	3,916,899	11/4/75	Theeuwes et al.			
	A122	3,845,770	11/5/74	Theeuwes et al.			
	A123	3,598,123	8/10/71	Zaffaroni et al.			
	A124	3,536,809	10/27/70	Applezweig			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	WO 03/086373	10/23/03	PCT				
	B02	WO 03/080049	10/2/03	PCT				
	B03	WO 03/080048	10/2/03	PCT				
	B04	WO 02/064083	8/22/02	PCT				
	B05	WO 01/70275	9/27/01	PCT				
	B06	WO 01/45702	6/28/01	PCT				
	B07	WO 01/34606	5/17/01	PCT				
	B08	WO 01/087307	11/22/01	PCT				
	B09	WO 99/06041	2/11/99	PCT				
	B10	WO 97/23457	7/3/97	PCT				
	B11	WO 97/08143	3/6/97	PCT				
	B12	WO 95/01348	1/12/95	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Alexanian et al., 2004, "VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma," Am. Soc. Hematol. 46 th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #210
	C02	Anderson, 2000, "Thalidomide: Therapeutic potential in hematologic malignancies," Seminars in Hematology 37(1 Supp 3): 1-4
	C03	Attal et al., 2004, "Maintenance treatment with thalidomide after autologous transplantation for myeloma: First analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02)," Am. Soc. Hematol. 46 th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #535
	C04	Bach, 1963, "Thalidomide in Cancer Chemotherapy," <i>The Lancet</i> , June 8, No. 1271, pg. 71
	C05	Bach, 1963, "Studies on the Possible Anti-Neoplastic Effect of Thalidomide," <i>Acta Pathologica Et Microbiologica Scandinavica</i> 59:491-499
	C06	Bernardeschi et al., 2003, "Low dose thalidomide plus monthly high-dose oral dexamethasone (thali-dexa): Results, prognostic factors and side effects in eight patients previously treated with multiple myeloma," J. Exp. Clin. Cancer Res. 22(Supp 4):129-133
	C07	Cartensen, 1995, Drug Stability: Principles & Practice, 2 nd ed., New York pp. 379-380
	C08	Chaundhry, 1966, "Effect of Prednisolone and Thalidomide on Induced Submandibular Gland Tumors in Hamster," <i>Cancer Research</i> 26(part 1):1884-86
	C09	Corral et al., 1999, "Immunomodulation by thalidomide and thalidomide analogues," Ann. Rheum. Dis. 58(Suppl 1):1107-113
	C10	Craig et al., 1967, "Potential anticancer agents. III. 2-phthalimidoaldehydes and derivatives," Potential Anticancer Agents III 10:1071-1073
	C11	D'Amato et al., 2001, "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma," Semin. Oncol. 28:597-601
	C12	D'Amato et al., 1994, "Thalidomide is an Inhibitor of Angiogenesis", Proc. Natl. Acad. Sci. 91:4082-4085
	C13	Davies et al., 2001, "Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma," Blood 98(1):210-216
	C14	De et al., 1976, "Hansch analysis for some antineoplastic glutarimides," J. Indian Chem. Soc. I.III: 825-826
	C15	De et al., 1976, "Possible antineoplastic agents: III. Synthesis of 6-alkyl-2-[4'-methoxyphthalimido] and 6-alkyl-3-[3'-4'-dimethoxyphenyl] glutarimides," J. Indian Chem. Soc. I.III:1122-1125
	C16	Dimopoulos et al., 2004, "Primary treatment with pulsed melphalan, dexamethasone, thalidomide (MDT) for symptomatic patients with multiple myeloma ≥75 years of age," Am. Soc. Hematol. 46 th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #1482
	C17	DiPaolo, June 26, 1964, "Thalidomide: Effects on Ehrlich Ascites Tumor Cells <i>in vitro</i> " Science 144:1583
	C18	DiPaolo, 1963, "Effect of Thalidomide on a Variety of Transplantable Tumors," <i>Cancer Chemotherapy Reports</i> No. 29, p. 99-102
	C19	DiPaolo, 1963, " <i>In vitro</i> Test Systems for Cancer Chemotherapy, II. Correlation of <i>in vitro</i> Inhibition of Dehydrogenase and Growth with <i>in vivo</i> Inhibition of Ehrlich Asoites Tumor," <i>Proceedings of the Society for Experimental Biology & Medicine</i> 114:384-387

C20	Dredge et al., 2002, "Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects," Br. J. Cancer 87(10):1166-1172
C21	Eisen et al., 2000, "Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer," Br. J. Cancer 82(4):812-817
C22	Emens et al., 2001, "Chemotherapy: friend or foe to cancer vaccines?" Curr. Opin. Mol. Ther. 3(1):77-84
C23	Fakhouri et al., 2004, "Thalidomide in patients with multiple myeloma and renal failure," Br. J. Haematol. 125:90-102
C24	Fenk et al., 2005, "Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma," Leukemia 19(1):156-159
C25	Folkman et al., 1983, "Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone," Science 221(4612):719-725
C26	Gershbein, 1991, "The thalidomide analog, EM 12, enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas," Cancer Letters 60: 129-133
C27	Grabstald et al., 1965, "Clinical experiences with thalidomide in patients with cancer," Clinical Pharmacology and Therapeutics 6:298-302
C28	Gupta et al., 2001, "Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications," Leukemia 15(12):1950-1961
C29	Haslett et al., 2003, "Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro," J. Infect. Dis. 187(6):946-955
C30	He, W., et al., 1993, Abstract of papers, 206th American Chemical Society, Chicago, IL; Med. Chem., paper 216
C31	Hideshima et al., 2000, "Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy," Blood 96(9):2943-2950
C32	Jonsson, 1972, "Chemical Structure and Teratogenic Properties," Acta Pharm., pp. 521-542.
C33	Lentzsch et al., 2003, "Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo," Leukemia 17(1):41-44
C34	Lentzsch et al., 2002, "S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice," Cancer Research 62:2300-2305
C35	Mauad, 1963, "Clinical Improvements Obtained in Advanced Cancer Patients with Treatment with Thalidomide Associated with Hormones," Anais Paulistas de Medicina e Cirurgia, 86:13-40
C36	Miyachi et al., 1997, "Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity," J. Med. Chem. 40:2858-2865
C37	Muckter, 1966, "Thalidomide and Tumor," Antimicrobial Agents and Chemotherapy pp. 531-538
C38	Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," Bioorg. Med. Chem. Lett. 9(11):1625-1630
C39	Muller et al., 1998, "Thalidomide analogs and PDE4 inhibition," Bioorg. Med. Chem. Lett. 8(19):2669-2674
C40	Muller et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity," J. Med. Chem. 39(17):3238-3240
C41	Offidani et al., 2003, "Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study," Haematologica 88(12):1432-1433
C42	Olson et al., 1965, "Thalidomide (N-phthaloylglutaramide) in the treatment of advanced cancer," Clinical Pharmacology and Therapeutics 6(3):292-297
C43	Palumbo et al., 2004, "A prospective randomized trial of oral melphalan prednisone, thalidomide (MPT) vs. oral melphalan, prednisone (MP): An interim analysis," Am. Soc. Hematol. 46 th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #207
C44	Penichet et al., 2001, "Antibody-cytokine fusion proteins for the therapy of cancer," J. Immunol. Methods 248(1-2):91-101
C45	Physicians' Desk Ref. 2002, 56 th ed., pp. 1755-1760
C46	Raje et al., 1999, "Thalidomide--a revival story," N. Engl. J. Med. 341(21):1606-1609
C47	Rajkumar et al., 2004, "Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): Results of a phase III trial coordinated by the Eastern Cooperative Oncology Group," Am. Soc. Hematol. 46 th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #205
C48	Rajkumar et al., 2000, "Prognostic value of bone marrow angiogenesis in multiple myeloma," Clin. Cancer Res. 6(8):3111-3116
C49	Raza et al., 2001, "Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes," Blood 98(4):958-965
C50	Ribatti et al., 1999, "Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma," Br. J. Cancer 79(3-4):451-455
C51	Roe et al., 1963, "Thalidomide and Neoplasia," Nature, December 7, 200:1016-17
C52	Shah et al., 1999, "Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis," J. Med. Chem. 42:3014-3017
C53	Shibata et al., 1995, "N-alkylphthalimides: structural requirement of thalidomide action on 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor production by human leukemia HL-60 cells," Chem.

		Pharm. Bull. 43(1):177-179
	C54	Shimazawa et al., 1999, "Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide," Biol. Pharm. Bull. 22(2):224-226
	C55	Singhal et al., 1999, "Antitumor activity of thalidomide in refractory multiple myeloma," N. Engl. J. Med. 341(21):1565-1571
	C56	Steins et al., 2002, "Efficacy and safety of thalidomide in patients with acute myeloid leukemia," Blood 99(3):834-839
	C57	Stockdale, 1998, <i>Medicine</i> , Rubenstein and Federman, eds., Vol. 3, Ch. 12, Sections IV and X
	C58	Sugiura et al., 1964, "Effect of thalidomide on transplantable mouse, rat, and hamster tumors," Gann. 55:57-60
	C59	Vacca et al., 1999, "Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma," Blood 93(9):3064-3073
	C60	Wohrer et al., 2004, "Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report," Hematol. J. 5:361-363
	C61	Wolff, ed., 1995, 1 Burger's Medicinal Chemistry and Drug Discovery, 5 th ed., 172-178, 949-982

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.